Sellas Life Sciences’ treatment of T-cell lymphoma was granted FDA orphan status, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLS:
- SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
- Sellas enrolls first patients in 60 mg dose cohort in Phase 2a SLS009 trial
- SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
- Largest borrow rate increases among liquid names
- SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia